Aspyrian Therapeutics Inc., a San Diego, CA-based clinical stage drug development company creating precision-targeted therapies to treat cancer based on its proprietary Photoimmunotherapy platform, secured $4.25m as part of a Series A extension financing.
The backers were not disclosed.
Led by Miguel Garcia-Guzman, Ph.D., President and Chief Scientific Officer, and Dr. Merrill Biel, M.D. Ph.D., Chief Medical Officer, Aspyrian is advancing RM-1929 is an antibody conjugate with a non-toxic payload (IRDye® 700DX) that targets a specific cancer antigen that is expressed in carcinomas allowing treatment of a number of different cancer types, including cancers of the head and neck, esophagus, lung, colon, and pancreas.
The conjugate is administered systemically but its pharmacological action is limited to the tumors where laser mediated activation triggers cancer cell killing.
The financing will support the execution of Phase 1 Clinical Studies of RM-1929, the company’s drug therapy for the treatment of patients with recurrent head and neck cancer.